La Chine prépare une révolution : le médicament — Transcript
Full transcript
- 0:00Barcelona, September 2024. Ivonicept, a
- 0:03new drug tested for lung cancer, is
- 0:06causing a seismic shift. For the first
- 0:09time, there was a new anticancer drug
- 0:12that outperformed the gold-standard
- 0:14American drug, Keytruda.
- 0:16And in your opinion, where does this
- 0:18new drug come from?
- 0:19It completely changed the perception of
- 0:21China. It was no longer just the
- 0:24world's factory copying the West. It
- 0:26was becoming the world's brain.
- 0:29On its own, ivonicept is the symbol of
- 0:31an industry in full transformation:
- 0:32biotech. An industry where eyes are
- 0:34increasingly turning toward the East,
- 0:37which has laboratories for molecule
- 0:39research, hospitals for testing,
- 0:42factories to manufacture drugs, and
- 0:45dormitories to house young doctors.
- 0:49Today, between 3,000 and 4,000 Chinese
- 0:50biotech firms, 150 of which are
- 0:52publicly traded, try every day to
- 0:54invent the drugs of tomorrow. And in
- 0:562024, for the first time, the majority
- 0:58of new molecules discovered globally
- 1:00came from China. There
- 1:02is an industrial reality, an
- 1:04entrepreneurship of Chinese companies
- 1:06that are now at the forefront.
- 1:08How can we explain this shift, and can
- 1:10the United States stop it? My name is
- 1:13Harold Grand, I am a video journalist
- 1:15at Les Échos, and today I'm taking you
- 1:16on a journey into the ultra-strategic
- 1:18world of Chinese pharmaceuticals. To
- 1:26understand how China carved out a place
- 1:28on the global drug map, we must return
- 1:31to the basics: the life cycle of a drug
- 1:33.
- 1:34What matters is the marketing
- 1:36authorization, or MA. This is Eric
- 1:40Bouteiller, a professor at the China
- 1:41Europe International Business School
- 1:43and author of a reference book on
- 1:45market access for pharmaceutical
- 1:46products. He lives in China 7 months a
- 1:49year, and he was kind enough to come to
- 1:51our air-conditioning-free studio during
- 1:53a heatwave while visiting Paris.
- 1:55Does that match what you're looking for
- 1:56or not?
- 1:56Yeah, that's great.
- 1:57Marketing authorization. That's what
- 2:00counts because from that moment on, you
- 2:02have the ability to sell a
- 2:04pharmaceutical product.
- 2:05Those who sell these pharmaceutical
- 2:07products are the laboratories that hold
- 2:08the rights via a patent. Sometimes they
- 2:11develop their products themselves;
- 2:12sometimes they buy this stage from
- 2:14other establishments specialized in
- 2:16medical research: biotechs. The
- 2:19development of a pharmaceutical product
- 2:20, in general, is something that takes
- 2:22an enormous amount of time. It takes
- 2:25about ten years, within a product life
- 2:27cycle of around 20 years or so.
- 2:31And later on, much later, something
- 2:32else happens.
- 2:33We enter into what we call the generics
- 2:35phase. The laboratory and obviously the
- 2:38biotech firm before it will lose all
- 2:40rights, and it becomes a product that
- 2:42can be manufactured by any generic
- 2:44company, provided it obviously complies
- 2:46with the pharmaceutical file submitted
- 2:48to the authorities.
- 2:50If I’m talking to you about generics,
- 2:51it’s because that’s the field in
- 2:53which China has excelled for decades,
- 2:54and it’s what laid the foundations
- 2:56for the explosion of biotechs in the
- 2:57country. Moreover, it’s the same
- 2:59pattern as in tech or the automotive
- 3:00industry. China first mastered
- 3:01logistics before innovating and
- 3:03flooding the market. Take the example
- 3:06of BYD, a small battery manufacturer
- 3:08that became the number one electric car
- 3:11manufacturer in 30 years, ahead of
- 3:13Tesla in 2025 with over 1.6 million
- 3:16models sold. China has succeeded in
- 3:20achieving significant health
- 3:22development in its country by
- 3:24establishing a generic industry,
- 3:26systematic copying, if you will. And it
- 3:29spent about twenty years since the
- 3:32country's opening, so from the 90s to
- 3:352015-16, trying to develop
- 3:37pharmaceutical innovation on its own.
- 3:41It went from the status of factory of
- 3:44the world to the lab of the world.
- 3:47Raphaël Baligieri is the Les Échos
- 3:48correspondent in China, and a few
- 3:50months ago, he spent several days in
- 3:52Suzhou, the new city dedicated to the
- 3:54medicines of tomorrow. Announced in
- 3:58October 2010 by the Central Committee
- 4:00of the Chinese Communist Party, the
- 4:0212th Five-Year Plan made biotechs one
- 4:04of the country's seven strategic
- 4:06emerging industries. In other words,
- 4:08China is beginning a new battle: that
- 4:10of research.
- 4:11And when I went to Suzhou recently to
- 4:14conduct this investigation on biotechs,
- 4:16well, I indeed realized that most of
- 4:19the biotechs I interviewed were born
- 4:21around 2010. And this is also explained
- 4:24, curiously, by the subprime crisis in
- 4:26the United States and the financial
- 4:28crisis, which actually forced a huge
- 4:30number of Chinese scientists who had
- 4:32left to pursue careers in the U.S. to
- 4:34return to China.
- 4:36And as an anecdote, these scientists
- 4:37even have a nickname: "sea turtles,"
- 4:39because they go back to lay their eggs
- 4:40where they were born. Employed in major
- 4:43American pharmaceutical labs like
- 4:44Pfizer, Merck, or Johnson&Johnson, they
- 4:47returned home to found their own
- 4:48companies. What was very surprising in
- 4:52Suzhou is that I actually did all my
- 4:54interviews in English with these
- 4:56Chinese scientists who had spent 10 or
- 4:5815 years in the U.S. and who had been
- 5:00drawn back like that by China, by the
- 5:03promise of its investments and public
- 5:05support.
- 5:07A promise accompanied by concrete
- 5:08reforms starting in 2015.
- 5:10Before 2015, there was an
- 5:13administrative way of operating since
- 5:172015-2016. This was coupled with
- 5:21top-tier scientific thinking. The
- 5:24Chinese drug agency has become one of
- 5:26the most scientific agencies in the
- 5:28world.
- 5:29As a result, marketing authorization
- 5:31procedures are speeding up, and more
- 5:34local clinical trials are recognized,
- 5:36reducing market access for patients by
- 5:38several years. Naturally, the entire
- 5:41drug manufacturing supply chain is
- 5:43entering a new dimension. A
- 5:45demonstration in Suzhou, 30 minutes by
- 5:47high-speed train from Shanghai, where
- 5:49over 650 biotechs have sprouted in a
- 5:51few years. What
- 5:52is striking, well, it's first of all
- 5:54its scale, since it's very large. So
- 5:58there are large tree-lined avenues, a
- 5:59DNA museum, and in fact, you find
- 6:01everything in this park. That is to say
- 6:05, there are laboratories for molecular
- 6:08research, and hospitals for testing on
- 6:11a large number of patients with huge
- 6:13amounts of data. There are factories to
- 6:17manufacture drugs, and dormitories to
- 6:20house young doctors and new recruits.
- 6:23Some researchers even told Raphaël
- 6:25that when they moved to Suzhou to
- 6:26launch their biotech, the authorities
- 6:28exempted them from rent for several
- 6:30months to give them time to generate
- 6:32initial income. And it doesn't stop
- 6:34there. The entity managing the
- 6:36industrial park, called BioBAY,
- 6:38invested the equivalent of 309 million
- 6:40euros in 2024 into venture capital
- 6:42funds dedicated to the biotech sector.
- 6:45You can have offices immediately and
- 6:48recruit young Chinese researchers who
- 6:50just finished their PhDs in China and
- 6:53are available right away for lower
- 6:55salaries than in the United States. And
- 6:59inevitably, at some point, it pays off.
- 7:04Back to Barcelona in late 2024. On the
- 7:07sidelines of the annual European
- 7:09oncology congress, an American biotech,
- 7:11Summit Therapeutics, unveils staggering
- 7:13results. One of these drugs, ivonimab,
- 7:16[outperforms] Keytruda, the world's
- 7:18best-selling drug by value, at 32
- 7:20billion dollars in 2025. Developed by
- 7:23the American giant Merck, it is the
- 7:25benchmark for lung cancer. It presented
- 7:28results showing it reduced the risk of
- 7:32disease progression and death by 49%
- 7:35compared to Keytruda in lung cancer.
- 7:38Myriam Chauveau is a journalist at Les
- 7:40Échos who covers the pharmaceutical
- 7:41sector. Okay, so now you're going to
- 7:43say, "Fine, Ivonimab is great, but what
- 7:45does it have to do with China?" Well,
- 7:47even if Summit Therapeutics holds the
- 7:49international marketing rights for the
- 7:50drug, this cancer treatment was
- 7:52initially developed by a Chinese
- 7:53biotech, Akeso. And Akeso’s story
- 7:56checks all the boxes for the perfect
- 7:58biotech according to Beijing. It was
- 7:59founded by Michelle Xia in 2012. This
- 8:02Chinese researcher, trained in the UK
- 8:04where she earned a PhD in molecular
- 8:06biology, honed her skills at Bayer in
- 8:08the US before returning to start a
- 8:10business in China. And just like that,
- 8:12another "sea turtle" returns home. From
- 8:14that moment on, it was a buying frenzy.
- 8:16Everyone wanted to buy the same thing
- 8:18as Ivonescimab. It was a complete
- 8:20change in perception of China within
- 8:22the pharma sector.
- 8:24Even though Western biotechs are in
- 8:25great shape at the start of this year
- 8:27with over 16 deals exceeding a billion
- 8:29dollars, it is China that is attracting
- 8:31the most funding. Since January 2026,
- 8:34American labs have invested 40 billion
- 8:36dollars in Chinese biotechs. That’s
- 8:38almost as much as in the entire
- 8:402020-2025 period. Chinese research is
- 8:42so bankable that some labs are taking
- 8:44the gamble of buying licenses for drugs
- 8:47that haven't even been tested on
- 8:48animals yet. We are talking about the
- 8:50preclinical stage. That’s what
- 8:52happened in December 2024. Merck
- 8:54shelled out 2 billion dollars to secure
- 8:57an obesity pill from Rionso Pharma, a
- 8:59Chinese lab. Today, you have major
- 9:03Western labs buying entire pipelines of
- 9:06drug candidates—meaning over a dozen
- 9:09drug candidates at once. And obviously,
- 9:13those buyouts exceed 10 billion dollars
- 9:15, right?
- 9:16At the end of May, Pfizer struck a deal
- 9:18with Suzhou-based biotech Innovent for
- 9:21a total of 10.5 billion dollars. And
- 9:23what you really need to understand is
- 9:25that it’s not just license purchases
- 9:27that are allowing Chinese research to
- 9:28thrive today.
- 9:29You can outright form a research
- 9:32cooperation agreement. That’s
- 9:34ultimately what Bristol Myers Squibb (
- 9:36BMS) did. They bought 13 drug
- 9:39candidates from the Chinese lab Jiangsu
- 9:42Hengrui. In reality, they didn’t buy
- 9:4613. Jiangsu Hengrui handed over the
- 9:50rights to four of its drug candidates.
- 9:53The American firm BMS brought in the
- 9:56rights to four of its own candidates,
- 10:00and the two actually struck a deal to
- 10:03co-develop five drug candidates. So,
- 10:06it’s no longer just a purchase;
- 10:08it’s genuine cooperation. And that
- 10:09cooperation can go even further. In
- 10:122024, a consortium of American
- 10:13financial investors bought four "
- 10:15coupefin" drug candidates developed by
- 10:17the same Chinese lab.
- 10:19And Jiangsu Hengrui received cash for
- 10:22the sale of its licenses immediately.
- 10:25But above all, Jangu Hang owns 20%of
- 10:28the capital of the Hercule company,
- 10:30which is the American firm where our
- 10:33drug candidate licenses were housed.
- 10:36the licenses for his drug candidates.
- 10:38So for him, it’s a real financial
- 10:40windfall for the future.
- 10:41After that, Hercule rebranded as
- 10:42Kailera Therapeutics and went public on
- 10:45the NASDAQ on April 16, 2026. This IPO
- 10:48allowed it to raise a record amount of
- 10:50625 million dollars. That’s more than
- 10:53the IPO of American giant Moderna,
- 10:54notably responsible for one of the
- 10:56Covid vaccines. A portion of this money
- 10:59is directed straight to the Chinese
- 11:00laboratory Diongué, thus funding
- 11:02Chinese research. As you can imagine,
- 11:04China's rise in power? Well, it makes
- 11:06some people sick. We must subject
- 11:12agreements reached by pharmaceutical
- 11:14companies with China to the same level
- 11:16of scrutiny we apply to investors in
- 11:18the Chinese technology sector.
- 11:21Otherwise, China will continue to
- 11:22appropriate American innovation and use
- 11:24it to drive our companies and
- 11:26industries into bankruptcy. Those are
- 11:28the words of John Moolenaar. He is an
- 11:29American Republican representative who
- 11:31heads a special committee on China. He
- 11:34just introduced a bill, the Biotech
- 11:36Investment National Security Act, which
- 11:38has one goal: hitting Beijing in the
- 11:41wallet. His idea: try to curb the
- 11:59development of a sector that currently
- 12:01depends primarily on private money. In
- 12:03France, a little over 12%of GDP is
- 12:05spent on health expenditures. In China,
- 12:08that figure drops to 7%.
- 12:09Today, China, from my point of view,
- 12:12does not spend enough on on on on on on
- 12:14healthcare. And so that explains why
- 12:17you have enormous distortions within
- 12:19the healthcare system. But the
- 12:22authorities don't want to solve these
- 12:24problems, they don't want to invest
- 12:26more, and they hope that the US or
- 12:28Europe will fund their biotech.
- 12:31The government's priority today is
- 12:33focused on AI, a sector where the
- 12:35Communist Party plans to invest 295
- 12:38billion dollars by 2030, and of course
- 12:40on defense, with a 239 billion dollar
- 12:43budget for the year 2026 alone. I dug
- 12:46through reports trying to find the
- 12:48budget for biotechs, but I didn't come
- 12:49across a precise figure. China
- 12:51China is a country with very
- 12:53significant strategic goals, and it is
- 12:55therefore making considerable
- 12:57investments in things that we should
- 12:59probably also follow very closely, but
- 13:01in any case, they aren't improving the
- 13:03health of Chinese patients.
- 13:06According to this April 2026 study by
- 13:08the BCG firm, only 36%of R&D spending
- 13:10in Chinese research depends on the
- 13:12government. For the rest, they have to
- 13:15find the money elsewhere, from major
- 13:16Western laboratories or dedicated
- 13:18investment funds.
- 13:20And in Suzhou, I met biotech firms that
- 13:22, well, took 10 to 15 years before
- 13:24bringing their first drugs to market.
- 13:27The Chinese state does not have the
- 13:29means to irrigate and fund its research
- 13:31system. So without license sales to
- 13:33Westerners, Chinese research would
- 13:35grind to a halt because it lacks the
- 13:37money. That is why the United States
- 13:39wants to hit them where it hurts, to
- 13:40stop feeding the beast and prevent
- 13:42Chinese biotech firms from becoming
- 13:43financially independent in the long run
- 13:45. What do we do if we lose that
- 13:47knowledge? Can we count on China in the
- 13:49future to recover lost knowledge? In my
- 13:51opinion, no. It is not in Chinese
- 13:54culture, once knowledge is in China, to
- 13:56share it with the competition. China
- 13:58tends to kill off its competition
- 14:00rather than share with it. The most
- 14:01famous story is still the one about
- 14:03silkworms in antiquity. When China was
- 14:07making a lot of money selling silk to
- 14:09the West, it prohibited, on pain of
- 14:11death, revealing the secrets of silk
- 14:13production to Western buyers; you
- 14:15weren't allowed to take silkworms out
- 14:18of China, and there were customs
- 14:20officers on the Silk Road. If they
- 14:23found silkworms in your luggage, you
- 14:24were put to death.
- 14:26Thank you for watching this analysis of
- 14:27Chinese biotech firms all the way to
- 14:28the end. If you want to dive deeper,
- 14:30I've put the link to the report I cited
- 14:31in the video in the description. It is
- 14:33technical, but it is fascinating. And I
- 14:35am including some links to articles by
- 14:36Raphaël and Myriam on the subject. Let
- 14:38me know in the comments if you would
- 14:40like us to cover more health topics,
- 14:41and if so, which specific ones. You can
- 14:43also find our videos on Spotify, Apple
- 14:45Music, and of course on the Les Échos
- 14:47website. Subscribe. I also like
- 14:49touching the microphone a bit. I think
- 14:50it makes it feel more relaxed, you know
- 14:51? A bit what?
About this transcript
This page contains the full transcript of La Chine prépare une révolution : le médicament by Les Echos, generated from the public captions YouTube serves with the video. The transcript has 2,389 words across 399 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.